Thrombotic disorders include some of the most serious clinical conditions in westernised societies, e.g. lung embolism, infarctus, strokes, dementia and acute organ failure. Despite extensive research, there is a lack of a diagnostic laboratory proceedures for these diseases and global (over-all) assays hardly perform at all. As the drug and diagnostics markets related to thrombotic disorders are huge (about 10billion ECU), global assays that explain the disorders and help develop effective drugs have tremendous commercial potential. The basis for the present project is our recent finding that, coagulation induced by endothelial cells is augmented in about 40% of thrombotic patients and clot dissolution and contact factor is impaired in some additional 40%. The project includes novel proprietary rheological technology allowing analysis of whole blood. The project goal is to produce a diagnostic package of reagents and apparatus for performing global assays for the diagnosis of thrombotic disorders.
Funding SchemeEAW - Exploratory awards
CT14 9JW Walmer / Deal - Kent